₹2,930.3
▼ -46.4 -1.56%
17 Jun 2026
NSE Listed · Healthcare
NGL Fine-Chem Limited (NGLFINE)
20-day avg volume: 34K shares
- Healthy return on equity of 15.7%.
- Revenue grew 36% YoY.
- Net profit is growing year over year.
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | ₹149 Cr | ₹128 Cr | ₹120 Cr | ₹104 Cr | ₹95 Cr |
| EBITDA | ₹24 Cr | ₹27 Cr | ₹19 Cr | ₹17 Cr | ₹5 Cr |
| Net Profit | ₹13 Cr | ₹16 Cr | ₹10 Cr | ₹9 Cr | ₹1 Cr |
| EPS | 21.83 | 25.4 | 15.58 | 14.96 | 0.88 |
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | ₹501 Cr | ₹368 Cr | ₹334 Cr | ₹274 Cr | — |
| EBITDA | ₹87 Cr | ₹42 Cr | ₹67 Cr | ₹40 Cr | — |
| Net Profit | ₹48 Cr | ₹21 Cr | ₹41 Cr | ₹20 Cr | — |
| EPS | — | 34.19 | 66.88 | 33.18 | 80.77 |
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | ₹545 Cr | ₹433 Cr | ₹356 Cr | ₹287 Cr | — |
| Total Liabilities | ₹216 Cr | ₹151 Cr | ₹93 Cr | ₹65 Cr | — |
| Equity | ₹329 Cr | ₹282 Cr | ₹263 Cr | ₹223 Cr | — |
| Total Debt | ₹109 Cr | ₹77 Cr | ₹34 Cr | ₹32 Cr | — |
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating | ₹43 Cr | ₹32 Cr | ₹20 Cr | ₹35 Cr | — |
| Investing | ₹-71 Cr | ₹-70 Cr | ₹-27 Cr | ₹-27 Cr | — |
| Financing | ₹30 Cr | ₹37 Cr | ₹-1 Cr | ₹-1 Cr | — |
| Free Cash Flow | ₹-47 Cr | ₹-42 Cr | ₹-8 Cr | ₹4 Cr | — |
Healthcare · Drug Manufacturers - General
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search
